BioWorld

July 26, 2006

View Archived Issues

Oscient Paying Reliant $78M For Cholesterol Drug In U.S.

Oscient Pharmaceuticals Inc. is gaining a piece of the fenofibrate market with its buyout of U.S. rights to the once-daily, cholesterol-lowering drug Antara from Reliant Pharmaceuticals Inc. for $78 million. (BioWorld Today) Read More

Encysive's Shares Plunge On 2nd Thelin Approvable Letter

Read More

Momenta Surges On Potential $260M Sandoz Collaboration

Read More

Altus Falls After Reporting Delay In Phase III Programs

Read More

Following TGN1412 Fiasco, Revised Rules Suggested

Read More

Other News To Note

Read More

Clinic Roundup

Read More